The Molecular Neuromodulation team works closely together with internationally leading AAV experts and clinicians to bring AAV based therapies for Parkinson’s disease to the clinic. The long-term goal of this project is to build a foundation of non-clinical and clinical experience to allow for rapid development of advanced, gene-based therapies in the future.